M Badr, MD
Pulmonary Disease · Detroit, MINPI 1568409563
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $3,745 with a category attached, or 66.8%. ZOLL Respicardia, Inc. accounts for 90.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $3,435 and has fallen 93.9% since, to $210 in 2025.
Across 7 payments — averaging $534.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$3K
- Jazz Pharmaceuticals Inc.$110
- Harmony Biosciences LLC$100
- Axsome Therapeutics, Inc.$100
- Genentech USA, Inc.$38
- GSK$13
Across 1 payment — averaging $42,866 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Resmed Corp$43K
What the payments were for
- Consulting fees$2,50067%
- Travel & lodging$88424%
- Food & beverage$2236%
- Education$1384%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 2 | $3,384 |
| Jazz Pharmaceuticals Inc. | 1 | $110 |
| Harmony Biosciences LLC | 1 | $100 |
| Axsome Therapeutics, Inc. | 1 | $100 |
| Genentech USA, Inc. | 1 | $38 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$3,384
- XYWAV$110
How this compares
$3,745 in reported general payments places this provider in the 65th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methadone Hcl | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Detroit
- Michael SimoffDetroit$149K
- Avi CohenDetroit$59K
- Labib Gilles DebianeDetroit$22K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.